Chung Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chung Lee has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Chang Gon Kim
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
3 shared publications - Minsun Jung
Department of Pathology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea
3 shared publications - Hyo Sup Shim
Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea
2 shared publications - Jongjin Yoon
Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2 shared publications - Sang Joon Shin
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
2 shared publications - Ahsen Ustaoglu
Early Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK
1 shared publication
Latest Publications
- Open Access
- 15 November 2026
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 60 (6) , 704-709
Meningioma harboring IDH1 R132H mutation: a case report
Meningiomas are the most common primary central nervous system tumors. Monosomy of chromosome 22 is the most frequently reported genetic abnormality in meningioma and the occurrence of IDH1 mutations in meningioma is exceedingly rare. We report an uncommon case of IDH1 R132H-mutant meningioma. A 69-year-old man presented with two intracranial masses, one of which was identified as an IDH1 R132H-mutant meningioma by next-generation sequencing and further confirmed by pyrosequencing and immunohistochemistry. The rarity of this molecular finding and the potentially favorable prognosis observed in previously reported cases highlight the need for its recognition as a distinct molecular subset. Isocitrate dehydrogenase–targeted therapy may represent a future therapeutic option, pending validation through prospective studies and larger case series.
- 15 November 2026
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 60 (6) , 704-709
Open AccessMeningioma harboring IDH1 R132H mutation: a case report
Meningiomas are the most common primary central nervous system tumors. Monosomy of chromosome 22 is the most frequently reported genetic abnormality in meningioma and the occurrence of IDH1 mutations in meningioma is exceedingly rare. We report an uncommon case of IDH1 R132H-mutant meningioma. A 69-year-old man presented with two intracranial masses, one of which was identified as an IDH1 R132H-mutant meningioma by next-generation sequencing and further confirmed by pyrosequencing and immunohistochemistry. The rarity of this molecular finding and the potentially favorable prognosis observed in previously reported cases highlight the need for its recognition as a distinct molecular subset. Isocitrate dehydrogenase–targeted therapy may represent a future therapeutic option, pending validation through prospective studies and larger case series.
- 21 August 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (11) , 895-903
Batch Effects in Tumor-Only Next-Generation Sequencing Panel Sequencing and Implications for Copy Number Variant Detection
- 21 August 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (11) , 895-903
Batch Effects in Tumor-Only Next-Generation Sequencing Panel Sequencing and Implications for Copy Number Variant Detection
- Open Access
- 31 July 2026
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 24 (2) , 109-118
GATA6 Alteration as a Potential Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated With Docetaxel After Androgen Receptor Pathway Inhibitor Failure
Purpose: This study aimed to evaluate the prognostic significance of GATA6 alterations in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel after androgen receptor pathway inhibitor (ARPI) failure.Materials and Methods: In this retrospective exploratory cohort study, patients with mCRPC who received docetaxel after prior ARPI therapy were included. Clinical and genomic data were reviewed, and Cox proportional hazards models were used to evaluate the prognostic impact of genomic alterations present in ≥5% of the cohort.Results: A total of 90 patients were analyzed (median age, 70.5 years; median follow-up, 17.7 months). GATA6 alteration was identified in 5 patients (5.6% of the cohort). In the gene-only analysis, GATA6 alteration was associated with shorter radiographic progression-free survival (rPFS) in both univariate (hazard ratio [HR], 7.44; 95% confidence interval [CI], 2.72–20.33; p<0.001) and multivariate models (HR, 5.15; 95% CI, 1.70–15.62; p=0.004). After adjustment for relevant clinical variables, GATA6 alteration remained significantly associated with shorter rPFS (HR, 7.38; 95% CI, 2.61–20.91; p<0.001). Kaplan-Meier analysis also showed shorter rPFS in patients with GATA6 alterations (log-rank p=0.005). GATA6 alteration was also associated with shorter prostate-specific antigen progression-free survival (PSA-PFS) in Cox analysis (HR, 7.37; p<0.001), and Kaplan- Meier analysis showed shorter PSA-PFS (log-rank p=0.037). For overall survival, GATA6 alteration showed a nonsignificant trend (HR, 2.15; p=0.106).Conclusion: GATA6 alteration was associated with shorter rPFS and PSA-PFS in this cohort and may be aprognostic biomarker of poor outcomes in patients receiving docetaxel after ARPI therapy. Further studiesare needed to validate these findings.
- 31 July 2026
- Published by Korean Urological Oncology Society in Journal of Urologic Oncology
- Vol. 24 (2) , 109-118
Open AccessGATA6 Alteration as a Potential Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated With Docetaxel After Androgen Receptor Pathway Inhibitor Failure
Purpose: This study aimed to evaluate the prognostic significance of GATA6 alterations in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel after androgen receptor pathway inhibitor (ARPI) failure.Materials and Methods: In this retrospective exploratory cohort study, patients with mCRPC who received docetaxel after prior ARPI therapy were included. Clinical and genomic data were reviewed, and Cox proportional hazards models were used to evaluate the prognostic impact of genomic alterations present in ≥5% of the cohort.Results: A total of 90 patients were analyzed (median age, 70.5 years; median follow-up, 17.7 months). GATA6 alteration was identified in 5 patients (5.6% of the cohort). In the gene-only analysis, GATA6 alteration was associated with shorter radiographic progression-free survival (rPFS) in both univariate (hazard ratio [HR], 7.44; 95% confidence interval [CI], 2.72–20.33; p<0.001) and multivariate models (HR, 5.15; 95% CI, 1.70–15.62; p=0.004). After adjustment for relevant clinical variables, GATA6 alteration remained significantly associated with shorter rPFS (HR, 7.38; 95% CI, 2.61–20.91; p<0.001). Kaplan-Meier analysis also showed shorter rPFS in patients with GATA6 alterations (log-rank p=0.005). GATA6 alteration was also associated with shorter prostate-specific antigen progression-free survival (PSA-PFS) in Cox analysis (HR, 7.37; p<0.001), and Kaplan- Meier analysis showed shorter PSA-PFS (log-rank p=0.037). For overall survival, GATA6 alteration showed a nonsignificant trend (HR, 2.15; p=0.106).Conclusion: GATA6 alteration was associated with shorter rPFS and PSA-PFS in this cohort and may be aprognostic biomarker of poor outcomes in patients receiving docetaxel after ARPI therapy. Further studiesare needed to validate these findings.
- Open Access
- 15 April 2026
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 58 (2) , 603-612
Efficacy and Safety of Ifosfamide and Mesna in Metastatic Castration-Resistant Prostate Cancer after Taxane-Based Chemotherapy and Novel Hormonal Therapy Failure
PurposeLimited treatment options exist for patients with metastatic castration-resistant prostate cancer (mCRPC) after the failure of taxane-based chemotherapy and novel hormonal therapy. Here, we report the safety and efficacy of ifosfamide and mesna in patients with mCRPC after the failure of taxane-based chemotherapy and novel hormonal therapy (NCT06236789).Materials and MethodsPatients with histologically confirmed prostate cancer who had failed taxane-based chemotherapy and novel hormonal therapy received ifosfamide 2,500 mg/m2 and mesna 1,500 mg/m2 on days 1–3, repeated every 21 days. Safety, objective response rate, disease control rate, reduction in serum prostate-specific antigen (PSA) concentration by >50% (PSA50) or >90% (PSA90), radiographic progression-free survival (rPFS), and overall survival (OS) were analyzed.ResultsA total of 47 patients with mCRPC were included in the study. The median number of lines of treatment was 5 (range, 3 to 7). All patients were previously administered docetaxel and novel hormonal therapies including abiraterone (51.1%) and/or enzalutamide (61.7%). Thirty-eight patients (80.9%) were administered cabazitaxel. The objective response and disease control rates were 21.3% and 80.9%, respectively. PSA50 and PSA90 were achieved in 31.9% and 10.6%, respectively. During a median follow-up duration of 54.3 months, rPFS and OS were 5.0 and 9.0 months, respectively. All the patients experienced treatment-related adverse events of any grades; however, no new safety signs were detected. Genomic biomarker analysis revealed that alterations in the TP53 pathway were associated with inferior rPFS and OS.ConclusionIfosfamide and mesna showed appreciable efficacy and manageable safety profiles in heavily treated patients with mCRPC.
- 15 April 2026
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 58 (2) , 603-612
Open AccessEfficacy and Safety of Ifosfamide and Mesna in Metastatic Castration-Resistant Prostate Cancer after Taxane-Based Chemotherapy and Novel Hormonal Therapy Failure
PurposeLimited treatment options exist for patients with metastatic castration-resistant prostate cancer (mCRPC) after the failure of taxane-based chemotherapy and novel hormonal therapy. Here, we report the safety and efficacy of ifosfamide and mesna in patients with mCRPC after the failure of taxane-based chemotherapy and novel hormonal therapy (NCT06236789).Materials and MethodsPatients with histologically confirmed prostate cancer who had failed taxane-based chemotherapy and novel hormonal therapy received ifosfamide 2,500 mg/m2 and mesna 1,500 mg/m2 on days 1–3, repeated every 21 days. Safety, objective response rate, disease control rate, reduction in serum prostate-specific antigen (PSA) concentration by >50% (PSA50) or >90% (PSA90), radiographic progression-free survival (rPFS), and overall survival (OS) were analyzed.ResultsA total of 47 patients with mCRPC were included in the study. The median number of lines of treatment was 5 (range, 3 to 7). All patients were previously administered docetaxel and novel hormonal therapies including abiraterone (51.1%) and/or enzalutamide (61.7%). Thirty-eight patients (80.9%) were administered cabazitaxel. The objective response and disease control rates were 21.3% and 80.9%, respectively. PSA50 and PSA90 were achieved in 31.9% and 10.6%, respectively. During a median follow-up duration of 54.3 months, rPFS and OS were 5.0 and 9.0 months, respectively. All the patients experienced treatment-related adverse events of any grades; however, no new safety signs were detected. Genomic biomarker analysis revealed that alterations in the TP53 pathway were associated with inferior rPFS and OS.ConclusionIfosfamide and mesna showed appreciable efficacy and manageable safety profiles in heavily treated patients with mCRPC.
- Open Access
- 24 November 2025
- Published by Springer Nature in Cancer Imaging
- Vol. 25 (1)
Computed tomography-based unsupervised clustering identifies clusters associated with progression free survival in clear cell renal cell carcinoma
Background: This study aimed to develop and validate a radiologic clustering model using CT imaging features to stratify clear cell renal cell carcinoma (ccRCC) patients by prognosis and identify key imaging predictors of 5-year progression free survival (PFS). Methods: This retrospective study included 164 ccRCC patients with multiphase kidney CT and next-generation sequencing (NGS) between September 2003 and October 2024. Qualitative imaging features were extracted, and unsupervised consensus clustering was performed to classify tumors based on radiologic characteristics. A nomogram-based C1 score was derived from features predictive of the high-risk cluster. Model performance was evaluated using C-index and 5-year area under the receiver operating curve (AUC). Genetic alterations and copy number variations (CNVs) were also analyzed for associations with imaging features and survival. Results: Clustering revealed two distinct radiologic subtypes. Cluster C1 characterized by aggressive behavior such as tumor heterogeneity ( p = 0.011), exophytic growth pattern ( p = 0.002), non-smooth margin ( p = 0.019), and renal sinus extension ( p = 0.016), and was independently associated with poorer 5-year PFS ( p = 0.018). The C1 score demonstrated an AUC of 0.992 for predicting cluster C1 in the test-set. Using a cutoff of 0.75, the model achieved 96.3% sensitivity and 96.4% specificity. For predicting 5-year PFS, the C1 score showed moderate performance (AUC 0.65; C-index 0.65), which improved when combined with nodal/distant metastasis and BAP1 mutation status (AUC 0.71; C-index 0.67). Conclusions: Radiologic clustering using CT features enables non-invasive prognostic stratification of ccRCC. The C1 score derived from this approach may serve as a practical tool to guide surveillance and treatment decisions. Trial registration: Retrospectively registered.
- 24 November 2025
- Published by Springer Nature in Cancer Imaging
- Vol. 25 (1)
Open AccessComputed tomography-based unsupervised clustering identifies clusters associated with progression free survival in clear cell renal cell carcinoma
Background: This study aimed to develop and validate a radiologic clustering model using CT imaging features to stratify clear cell renal cell carcinoma (ccRCC) patients by prognosis and identify key imaging predictors of 5-year progression free survival (PFS). Methods: This retrospective study included 164 ccRCC patients with multiphase kidney CT and next-generation sequencing (NGS) between September 2003 and October 2024. Qualitative imaging features were extracted, and unsupervised consensus clustering was performed to classify tumors based on radiologic characteristics. A nomogram-based C1 score was derived from features predictive of the high-risk cluster. Model performance was evaluated using C-index and 5-year area under the receiver operating curve (AUC). Genetic alterations and copy number variations (CNVs) were also analyzed for associations with imaging features and survival. Results: Clustering revealed two distinct radiologic subtypes. Cluster C1 characterized by aggressive behavior such as tumor heterogeneity ( p = 0.011), exophytic growth pattern ( p = 0.002), non-smooth margin ( p = 0.019), and renal sinus extension ( p = 0.016), and was independently associated with poorer 5-year PFS ( p = 0.018). The C1 score demonstrated an AUC of 0.992 for predicting cluster C1 in the test-set. Using a cutoff of 0.75, the model achieved 96.3% sensitivity and 96.4% specificity. For predicting 5-year PFS, the C1 score showed moderate performance (AUC 0.65; C-index 0.65), which improved when combined with nodal/distant metastasis and BAP1 mutation status (AUC 0.71; C-index 0.67). Conclusions: Radiologic clustering using CT features enables non-invasive prognostic stratification of ccRCC. The C1 score derived from this approach may serve as a practical tool to guide surveillance and treatment decisions. Trial registration: Retrospectively registered.
- Open Access
- 1 May 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (3) , 101533
In vivo consequences of varying degrees of OTOA alteration elucidated using knock-in mouse models and pseudogene contamination-free long-read sequencing
- 1 May 2025
- Published by KEAI Publishing in Genes & Diseases
- Vol. 12 (3) , 101533
Open AccessIn vivo consequences of varying degrees of OTOA alteration elucidated using knock-in mouse models and pseudogene contamination-free long-read sequencing
- Open Access
- 15 October 2023
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 55 (4) , 1087-1095
Clinicopathological Characteristics of NRG1 Fusion–Positive Solid Tumors in Korean Patients
Purpose Neuregulin 1 (NRG1) gene fusion is a potentially actionable oncogenic driver. The oncoprotein binds to ERBB3-ERBB2 heterodimers and activates downstream signaling, supporting a therapeutic approach for inhibiting ERBB3/ERBB2. However, the frequency and clinicopathological features of solid tumors harboring NRG1 fusions in Korean patients remain largely unknown.Materials and Methods We reviewed archival data from next-generation sequencing panel tests conducted at a single institution, specifically selecting patients with in-frame fusions that preserved the functional domain. The clinicopathological characteristics of patients harboring NRG1 fusions were retrospectively reviewed.Results Out of 8,148 patients, NRG1 fusions were identified in 22 patients (0.27%). The average age of the patients was 59 years (range, 32 to 78 years), and the male-to-female ratio was 1:1.2. The lung was the most frequently observed primary site (n=13), followed by the pancreaticobiliary tract (n=3), gastrointestinal tract (n=2, stomach and rectum each), ovary (n=2), breast (n=1), and soft tissue (n=1). Histologically, all tumors demonstrated adenocarcinoma histology, with the exception of one case of sarcoma. CD74 (n=8) and SLC3A2 (n=4) were the most frequently identified fusion partners. Dominant features included the presence of fewer than three co-occurring genetic alterations, a low tumor mutation burden, and low programmed death-ligand 1 expression. Various clinical responses were observed in patients with NRG1 fusions.Conclusion Despite the rarity of NRG1 fusions in Korean patients with solid tumors, identification through next-generation sequencing enables the possibility of new targeted therapies.
- 15 October 2023
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 55 (4) , 1087-1095
Open AccessClinicopathological Characteristics of NRG1 Fusion–Positive Solid Tumors in Korean Patients
Purpose Neuregulin 1 (NRG1) gene fusion is a potentially actionable oncogenic driver. The oncoprotein binds to ERBB3-ERBB2 heterodimers and activates downstream signaling, supporting a therapeutic approach for inhibiting ERBB3/ERBB2. However, the frequency and clinicopathological features of solid tumors harboring NRG1 fusions in Korean patients remain largely unknown.Materials and Methods We reviewed archival data from next-generation sequencing panel tests conducted at a single institution, specifically selecting patients with in-frame fusions that preserved the functional domain. The clinicopathological characteristics of patients harboring NRG1 fusions were retrospectively reviewed.Results Out of 8,148 patients, NRG1 fusions were identified in 22 patients (0.27%). The average age of the patients was 59 years (range, 32 to 78 years), and the male-to-female ratio was 1:1.2. The lung was the most frequently observed primary site (n=13), followed by the pancreaticobiliary tract (n=3), gastrointestinal tract (n=2, stomach and rectum each), ovary (n=2), breast (n=1), and soft tissue (n=1). Histologically, all tumors demonstrated adenocarcinoma histology, with the exception of one case of sarcoma. CD74 (n=8) and SLC3A2 (n=4) were the most frequently identified fusion partners. Dominant features included the presence of fewer than three co-occurring genetic alterations, a low tumor mutation burden, and low programmed death-ligand 1 expression. Various clinical responses were observed in patients with NRG1 fusions.Conclusion Despite the rarity of NRG1 fusions in Korean patients with solid tumors, identification through next-generation sequencing enables the possibility of new targeted therapies.
- Open Access
- 31 July 2021
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 54 (7) , 386-391
Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim & Myung-Ju Ahn. BMB Reports 2021;54:386-91. https://doi.org/10.5483/BMBRep.2021.54.7.045
- 31 July 2021
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 54 (7) , 386-391
Open AccessPaired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim & Myung-Ju Ahn. BMB Reports 2021;54:386-91. https://doi.org/10.5483/BMBRep.2021.54.7.045
- Open Access
- 1 May 2021
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 320 (5) , G804-G815
Heartburn sensation in nonerosive reflux disease: pattern of superficial sensory nerves expressing TRPV1 and epithelial cells expressing ASIC3 receptors
The underlying causes of heartburn, characteristic symptom of gastroesophageal reflux disease (GERD), remain incompletely understood. Superficial afferent innervation of the esophageal mucosa in nonerosive reflux disease (NERD) may drive nociceptive reflux perception, but its acid-sensing role has not yet been established. Transient receptor potential vanilloid subfamily member-1 (TRPV1), transient receptor potential melastatin 8 (TRPM8), and acid-sensing ion channel 3 (ASIC3) are regulators of sensory nerve activity and could be important reflux-sensing receptors within the esophageal mucosa. We characterized TRPV1, TRPM8, and ASIC3 expression in esophageal mucosa of patients with GERD. We studied 10 patients with NERD, 10 with erosive reflux disease (ERD), 7 with functional heartburn (FH), and 8 with Barrett’s esophagus (BE). Biopsies obtained from the distal esophageal mucosa were costained with TRPV1, TRPM8, or ASIC3, and CGRP, CD45, or E-cadherin. RNA expression of TRPV1, TRPM8, and ASIC3 was assessed using qPCR. Patients with NERD had significantly increased expression of TRPV1 on superficial sensory nerves compared with ERD (P = 0.028) or BE (P = 0.017). Deep intrapapillary nerve endings did not express TRPV1 in all phenotypes studied. ASIC3 was exclusively expressed on epithelial cells most significantly in patients with NERD and ERD (P ≤0.0001). TRPM8 was expressed on submucosal CD45+ leukocytes. Superficial localization of TRPV1-immunoreactive nerves in NERD, and increased ASIC3 coexpression on epithelial cells in NERD and ERD, suggests a mechanism for heartburn sensation. Esophageal epithelial cells may play a sensory role in acid reflux perception and act interdependently with TRPV1-expressing mucosal nerves to augment hypersensitivity in patients with NERD, raising the enticing possibility of topical antagonists for these ion channels as a therapeutic option. NEW & NOTEWORTHY We demonstrate for the first time that increased pain perception in patients with nonerosive reflux disease likely results from expression of acid-sensitive channels on superficial mucosal afferents and esophageal epithelial cells, raising the potential for topical therapy.
- 1 May 2021
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 320 (5) , G804-G815
Open AccessHeartburn sensation in nonerosive reflux disease: pattern of superficial sensory nerves expressing TRPV1 and epithelial cells expressing ASIC3 receptors
The underlying causes of heartburn, characteristic symptom of gastroesophageal reflux disease (GERD), remain incompletely understood. Superficial afferent innervation of the esophageal mucosa in nonerosive reflux disease (NERD) may drive nociceptive reflux perception, but its acid-sensing role has not yet been established. Transient receptor potential vanilloid subfamily member-1 (TRPV1), transient receptor potential melastatin 8 (TRPM8), and acid-sensing ion channel 3 (ASIC3) are regulators of sensory nerve activity and could be important reflux-sensing receptors within the esophageal mucosa. We characterized TRPV1, TRPM8, and ASIC3 expression in esophageal mucosa of patients with GERD. We studied 10 patients with NERD, 10 with erosive reflux disease (ERD), 7 with functional heartburn (FH), and 8 with Barrett’s esophagus (BE). Biopsies obtained from the distal esophageal mucosa were costained with TRPV1, TRPM8, or ASIC3, and CGRP, CD45, or E-cadherin. RNA expression of TRPV1, TRPM8, and ASIC3 was assessed using qPCR. Patients with NERD had significantly increased expression of TRPV1 on superficial sensory nerves compared with ERD (P = 0.028) or BE (P = 0.017). Deep intrapapillary nerve endings did not express TRPV1 in all phenotypes studied. ASIC3 was exclusively expressed on epithelial cells most significantly in patients with NERD and ERD (P ≤0.0001). TRPM8 was expressed on submucosal CD45+ leukocytes. Superficial localization of TRPV1-immunoreactive nerves in NERD, and increased ASIC3 coexpression on epithelial cells in NERD and ERD, suggests a mechanism for heartburn sensation. Esophageal epithelial cells may play a sensory role in acid reflux perception and act interdependently with TRPV1-expressing mucosal nerves to augment hypersensitivity in patients with NERD, raising the enticing possibility of topical antagonists for these ion channels as a therapeutic option. NEW & NOTEWORTHY We demonstrate for the first time that increased pain perception in patients with nonerosive reflux disease likely results from expression of acid-sensitive channels on superficial mucosal afferents and esophageal epithelial cells, raising the potential for topical therapy.
- 25 November 2016
- Published by The Korea Society for Child Education (KSCE) in The Korean Society for Child Education
- Vol. 25 (4) , 337-349
The Effects of Parental Attachment, Adaptation to School life and Resilience on Children's Happiness
본 연구의 목적은 아동의 회복탄력성, 부모와의 애착, 학교생활 적응이 아동의 행복감에 어떠한 영향을 미치는지 파악함으로써, 아동의 행복감 증진을
- 25 November 2016
- Published by The Korea Society for Child Education (KSCE) in The Korean Society for Child Education
- Vol. 25 (4) , 337-349
The Effects of Parental Attachment, Adaptation to School life and Resilience on Children's Happiness
본 연구의 목적은 아동의 회복탄력성, 부모와의 애착, 학교생활 적응이 아동의 행복감에 어떠한 영향을 미치는지 파악함으로써, 아동의 행복감 증진을